Bafna Pharma FY26 Revenue ₹1,506M, Net Profit ₹111M
Bafna Pharmaceuticals Ltd has released its Annual Report for FY 2025-2026, detailing significant financial growth and strategic expansion. The company reported operating revenue of INR 1,506 million, a 3.26% increase, with operating profit at INR 159 million, up 43%. Net profit saw a substantial surge of 167% to INR 111 million. The report highlights the company's expanding global footprint across 20+ countries, enhanced CRAMS capabilities, and investments in green energy and R&D. Bafna Pharmaceuticals also announced its 31st Annual General Meeting (AGM) scheduled for September 11, 2026, to be held via Video Conferencing, with CDSL providing E-Voting and VC/OAVM facilities. The company's manufacturing facility holds Tier-1 regulatory accreditations, and its export-driven model contributes significantly to revenue.
Key Highlights
- FY26 operating revenue reached INR 1,506 million with 3.26% growth.
- Net profit surged 167% to INR 111 million in FY26.
- Global footprint expanded to over 20 countries.
- 31st AGM scheduled for September 11, 2026, via VC/OAVM.
- Manufacturing facility holds UK-MHRA, EU-GMP, TGA, WHO-GMP accreditations.
Price Impact
More from BAFNAPH